- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | CLLS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 394.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AOMR | CLLS |
|---|---|---|
| Price | $8.01 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $11.08 | $8.33 |
| AVG Volume (30 Days) | 110.5K | ★ 159.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.18% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.38 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.93 | $1.25 |
| 52 Week High | $9.70 | $5.48 |
Technical Indicators
Market Signals| Indicator | AOMR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 22.61 |
| Support Level | N/A | N/A |
| Resistance Level | $9.24 | $3.47 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 14.13 | 11.57 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.